BPI fold containing family A member 3Genealiases: C20orf71 · SPLUNC3
Q-omics provides the consensus-scored BPIFA3 profile across patient tissues and cancer cell-line models. BPIFA3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BPIFA3 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, BPIFA3 protein abundance shows 12,330 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, COAD, and PDAC as cancer lineages where BPIFA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFA3 survival associations across molecular data types. BPIFA3 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFA3 RNA expression–survival associations across cancer types. High BPIFA3 expression shows unfavorable associations in ACC, PAAD, UCS, LIHC and OV, but favorable associations in HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BPIFA3 RNA expression.
This table summarizes BPIFA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BPIFA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFA3 shows lower tumor expression in KIRC and higher tumor expression in COAD. The COAD box plot shows higher BPIFA3 RNA expression in tumor versus normal tissue (log2 FC = +0.007, t-test p = .031).
This table shows molecular features associated with BPIFA3 in patient tissues and cancer cell lines. In patient samples, BPIFA3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, BPIFA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and STOMACH.
